Recent Finacing
Recent Raise
ProNAi Therapeutics develops DNAi nucleic-acid therapeutics using single-stranded DNA oligonucleotides delivered IV via pH‑tunable liposomal SMARTICLES, advancing PNT2258 targeting BCL2 in lymphoma and pipeline targets like CMYC, KRAS.
